Find comprehensive information on malignant tumor of prostate, including ICD-10 code C61, clinical documentation requirements, and healthcare resources. Learn about prostate cancer diagnosis, treatment options, and staging. This resource provides essential information for medical professionals, coders, and patients seeking information on malignant neoplasm of the prostate. Explore details on pathology, prognosis, and the latest research related to prostate malignancy.
Also known as
Malignant neoplasm of prostate
Cancers specifically affecting the prostate gland.
Secondary malignant neoplasms
Cancers that have spread to other sites from the primary location.
Persons encountering health services
Encounters for screening or other health services related to cancer.
Personal history of malignant neoplasm
Indicates a past diagnosis of cancer, including prostate cancer.
When to use each related code
| Description |
|---|
| Prostate Cancer |
| Prostatic Intraepithelial Neoplasia |
| Benign Prostatic Hyperplasia |
Incorrect or missing Gleason score impacting accurate C61 code assignment, affecting DRG and reimbursement.
Insufficient clinical documentation of tumor stage (TNM) leading to inaccurate code selection and risk stratification.
Missing or incorrect documentation of laterality (right, left, bilateral) affecting proper code assignment for C61.
Q: What are the most effective current guidelines for staging and risk stratification of malignant tumors of the prostate in newly diagnosed patients?
A: Current guidelines for staging and risk stratification of malignant prostate tumors emphasize a multi-modal approach combining clinical findings (digital rectal exam, PSA levels), imaging (multiparametric MRI), and biopsy results (Gleason score). The National Comprehensive Cancer Network (NCCN) guidelines recommend risk stratification based on these factors to guide treatment decisions, ranging from active surveillance for low-risk disease to radical prostatectomy or radiation therapy for intermediate and high-risk disease. Accurate staging is crucial for personalized treatment planning and optimizing patient outcomes. Explore how incorporating the latest NCCN guidelines can improve your clinical practice.
Q: How can I differentiate between indolent and aggressive prostate cancer using advanced imaging techniques and biomarkers beyond PSA?
A: Differentiating indolent from aggressive prostate cancer requires going beyond PSA levels and incorporating advanced imaging like multiparametric MRI, which can identify suspicious lesions and guide targeted biopsies. Biomarkers such as prostate health index (PHI), 4Kscore, and PCA3 can enhance risk stratification and aid in decision-making regarding active surveillance versus definitive treatment. Furthermore, genomic testing, such as Decipher Prostate, can provide prognostic information for patients with localized prostate cancer, aiding in treatment decisions and predicting the likelihood of adverse pathology. Consider implementing a multi-modal approach using advanced imaging and biomarkers to improve patient risk stratification and personalize treatment plans.
Patient presents with concerns regarding prostate health, including symptoms such as urinary frequency, urgency, nocturia, weak stream, hesitancy, straining, and or intermittent hematuria. Differential diagnosis includes benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. Digital rectal examination (DRE) revealed an enlarged prostate with or without palpable nodules or induration. Prostate-specific antigen (PSA) level was elevated above age-specific reference range. Transrectal ultrasound (TRUS) guided biopsy of the prostate was performed. Histopathological examination confirmed the diagnosis of malignant tumor of the prostate, adenocarcinoma. Gleason score was determined to be [insert Gleason score], indicating [insert Gleason score interpretation, e.g., low, intermediate, or high-grade cancer]. Staging workup, including bone scan, CT scan of the abdomen and pelvis, and or MRI, was conducted to assess for local and distant metastasis. The patient was diagnosed with [insert TNM stage] prostate cancer. Treatment options, including active surveillance, radical prostatectomy, radiation therapy (external beam radiation therapy or brachytherapy), hormone therapy (androgen deprivation therapy), chemotherapy, and or immunotherapy, were discussed with the patient. Patient elected to pursue [insert chosen treatment plan]. Risks, benefits, and alternatives of each treatment modality were thoroughly explained. Patient demonstrates understanding of the diagnosis, prognosis, and treatment plan. Follow-up appointment scheduled for [insert date] to monitor treatment response and manage potential side effects. Prognosis discussed, including survival rate and quality of life considerations. ICD-10 code C61 is recorded for malignant neoplasm of prostate.